108381-28-8

Basic information

• Product Name: 4-BENZYLOXY-2-CHLOROPYRIMIDINE
• Synonyms: 4-BENZYLOXY-2-CHLOROPYRIMIDINE;PyriMidine, 2-chloro-4-(phenylMethoxy)-
• CAS NO: 108381-28-8
• Molecular Formula: C₁₁H₉ClN₂O
• Molecular Weight: 220.65
• Mol File: 108381-28-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 387 °C at 760 mmHg
• Flash Point: 187.9 °C
• Appearance: /
• Density: 1.278g/cm³
• Vapor Pressure: 7.57E-06mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.06±0.20(Predicted)
• CAS DataBase Reference: 4-BENZYLOXY-2-CHLOROPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYLOXY-2-CHLOROPYRIMIDINE(108381-28-8)
• EPA Substance Registry System: 4-BENZYLOXY-2-CHLOROPYRIMIDINE(108381-28-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• Hazardous Substances Data: 108381-28-8(Hazardous Substances Data)

Usage

General Description

4-BENZYLOXY-2-CHLOROPYRIMIDINE is a chemical compound with the molecular formula C12H10ClN2O. It is a pyrimidine derivative that contains a benzyl ether group and a chlorine atom attached to the pyrimidine ring. 4-BENZYLOXY-2-CHLOROPYRIMIDINE has potential applications in the field of pharmaceuticals, agrochemicals, and material science. It may be used as an intermediate in the synthesis of various biologically active compounds and may also have pesticidal properties. Additionally, its unique structure and reactivity make it a valuable building block for the development of new materials and drug molecules. However, its specific properties and potential uses may vary depending on the exact synthesis and purification methods used.

InChI:InChI=1/C11H9ClN2O/c12-11-13-7-6-10(14-11)15-8-9-4-2-1-3-5-9/h1-7H,8H2

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1268273-86-4 4-(benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidine 
• 1268273-87-5 4-(benzyloxy)-5-iodo-2-(4-methylpiperazin-1-yl)pyrimidine 
• 1268273-88-6 3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)-aniline 
• 1268275-83-7 N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)acetamide 
• 1268273-89-7 N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)benzamide 
• 1268273-90-0 2-amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)acetamide 
• 1214242-43-9 (S)-tert-butyl 1-(6-(4-(benzyloxy)pyrimidin-2-yl)quinolin-4-yl)piperidin-3-ylcarbamate 
• 19810-62-9 4-benzyloxy-2-dimethylaminopyrimidine 

Relevant articles and documents

Diazaphenoxazines and Diazaphenothiazines: Synthesis of the "correct" Isomers Reveals They Are Highly Reactive Radical-Trapping Antioxidants

The preparation of 2,4-diazaphenothiazines and 2,4-diazaphenoxazines via a copper-catalyzed intramolecular amination is described. Literature approaches which utilize easily accessed (2′-aminophenyl) 4-pyri(mi)dyl sulfides undergo a Smiles rearrangement that gives rise to the 1,3-diaza derivatives instead, confirmed by X-ray crystallography. Inversion of the polarity of the cyclization avoids the rearrangement and affords the desired products. Preliminary kinetic studies suggest that 2,4-diazaphenothiazines and diazaphenoxazines, but not the 1,3-diaza isomers, are remarkably potent radical-trapping antioxidants.

HETEROCYCLIC GLP-1 AGONISTS

Provided are GLP-1 agonists of Formula (I) or (II), including pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions, and methods of using the same.

Heat shock protein 70 inhibitors. 2. 2,5′-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70

The discovery and development of heat shock protein 70 (Hsp70) inhibitors is currently a hot topic in cancer. In the preceding paper in this issue (10.1021/jm401551n), we have described structure-activity relationship studies in the first Hsp70 inhibitor class rationally designed to bind to a novel allosteric pocket located in the N-terminal domain of the protein. These ligands contained an acrylamide to take advantage of an active cysteine embedded in the allosteric pocket and acted as covalent protein modifiers upon binding. Here, we perform chemical modifications around the irreversible inhibitor scaffold to demonstrate that covalent modification is not a requirement for activity within this class of compounds. The study identifies derivative 27c, which mimics the biological effects of the irreversible inhibitors at comparable concentrations. Collectively, the back-to-back manuscripts describe the first pharmacophores that favorably and selectively interact with a never explored pocket in Hsp70 and provide a novel blueprint for a cancer-oriented development of Hsp70-directed ligands.